AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1933356 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg i.v.)
Number of subjects: 0
Study 1933356 — intervention group
Group type: COMPARATOR
Intervention: Saline (control placebo)
Number of subjects: 0
Study 7033916 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training tapes with female voice
Number of subjects: 76
Study 7033916 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training tapes with male voice
Number of subjects: 76
Study 7033916 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training tapes with musical background
Number of subjects: 76
Study 7033916 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training tapes with environmental background
Number of subjects: 76
Study 7033916 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training tapes (both male and female voices)
Number of subjects: 76
Study 30817628 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVI-daFIT! intervention (HIIT program)
Number of subjects: 10
Study 30817628 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular physical education sessions)
Number of subjects: 10
Study 29046301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400 IU/d, 2000 IU/d, or 4000 IU/d)
Number of subjects: 301
Study 29046301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D inadequacy (serum 25-hydroxyvitamin D concentration <50 nmol/L)
Number of subjects: 301
Study 29046301 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline obesity (BMI ≥30)
Number of subjects: 301
Study 29046301 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial/Ethnic differences
Number of subjects: 301
Study 25431239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/atorvastatin FDC 10/20 mg
Number of subjects: 633
Study 25431239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/atorvastatin FDC 10/40 mg
Number of subjects: 633
Study 24398143 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 240
Study 24398143 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 240
Study 24398143 — intervention group
Group type: COMPARATOR
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 240
Study 21712713 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedles for lidocaine injection
Number of subjects: 15
Study 21712713 — intervention group
Group type: COMPARATOR
Intervention: Hypodermic needles for lidocaine injection (control)
Number of subjects: 15
Study 19365287 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory intervention for workplace improvement
Number of subjects: 97
Study 19365287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 97
Study 17521544 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous mononuclear bone marrow cells (Group I; n=10)
Number of subjects: 30
Study 17521544 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic administration of granulocyte colony-stimulating factor (G-CSF) (Group II; n=10)
Number of subjects: 30
Study 17521544 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group III; n=10)
Number of subjects: 30
Study 14725484 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (6%)
Number of subjects: 52
Study 14725484 — intervention group
Group type: COMPARATOR
Intervention: HES 200/0.5 (6%)
Number of subjects: 52
Study 12031746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound group
Number of subjects: 300
Study 12031746 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 9694705 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (RA) in combination with daunorubicin and cytarabine (DA)
Number of subjects: 20
Study 9694705 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin and cytarabine (DA) only
Number of subjects: 20
Study 9694705 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (RA)
Number of subjects: 20
Study 8124802 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (10 mmol/d)
Number of subjects: 36
Study 8124802 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (350 mmol/d)
Number of subjects: 36
Study 2505485 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% acyclovir ophthalmic ointment
Number of subjects: 50
Study 2505485 — intervention group
Group type: COMPARATOR
Intervention: 2% trifluorothymidine (TFT) ophthalmic ointment
Number of subjects: 50
Study 371690 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (16 mg, injected 1 hour before cytostatic therapy)
Number of subjects: 14
Study 371690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 371690 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 14
Study 31566680 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy plus endocrine therapy
Number of subjects: 1389
Study 30528218 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (maximum dose of 2000 mg per day)
Number of subjects: 514
Study 30528218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study 30528218 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 514
Study 28416199 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with heart failure (HF)
Number of subjects: 10135
Study 28416199 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LVEF ≤40%
Number of subjects: 10135
Study 28416199 — intervention group
Group type: COMPARATOR
Intervention: Patients without heart failure (HF)
Number of subjects: 10135
Study 25533574 — intervention group
Group type: EXPERIMENTAL
Intervention: TCST program (12 weeks)
Number of subjects: 81
Study 25533574 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 81
Study 24021604 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary physical treatment method to stimulate arteriolar vasomotion
Number of subjects: 50
Study 24021604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20971747 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 17802
Study 20971747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17802
Study 19713130 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 66
Study 19713130 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic bilateral occlusion of uterine arteries
Number of subjects: 66
Study 17227688 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency zoster vaccine (approximately 207,000 plaque-forming units/dose)
Number of subjects: 698
Study 17227688 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-potency zoster vaccine (approximately 58,000 plaque-forming units/dose)
Number of subjects: 698
Study 17227688 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency zoster vaccine
Number of subjects: 698
Study 17227688 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-potency zoster vaccine
Number of subjects: 698
Study 15121488 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg single dose)
Number of subjects: 20
Study 15121488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11304900 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-strength grapefruit juice
Number of subjects: 14
Study 11304900 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 14
Study 11304900 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 14
Study 9207599 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (follitropin beta, Puregon)
Number of subjects: 1160
Study 9207599 — intervention group
Group type: COMPARATOR
Intervention: Urinary gonadotropins (hMG or urinary FSH)
Number of subjects: 1160
Study 8250683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 39
Study 8250683 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 39
Study 3117403 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intravesical chemotherapy (ADM 30 mg/30 ml, ADM 20 mg/40 ml, MMC 20 mg/40 ml) administered twice a week for 4 weeks after TUR
Number of subjects: 1182
Study 3117403 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term intravesical chemotherapy (ADM 30 mg/30 ml, ADM 20 mg/40 ml, MMC 20 mg/40 ml) administered twice a week for 1 week, every 2 weeks for 7 weeks, monthly for 8 months, and finally once every 3 months for 1 year
Number of subjects: 1182
Study 3117403 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 1182
Study 31725060 — intervention group
Group type: EXPERIMENTAL
Intervention: MCH‐ART arm (integrated maternal and child health services)
Number of subjects: 471
Study 31725060 — intervention group
Group type: COMPARATOR
Intervention: Standard of care arm (immediate transfer to general ART services)
Number of subjects: 471
Study 31725060 — intervention group
Group type: EXPERIMENTAL
Intervention: MCH‐ART arm
Number of subjects: 471
Study 31725060 — intervention group
Group type: COMPARATOR
Intervention: Standard of care arm
Number of subjects: 471
Study 29424469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (systolic BP < 120 mm Hg)
Number of subjects: 1000
Study 29424469 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (systolic BP < 140 mm Hg)
Number of subjects: 1000
Study 27776530 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical CryoMaze followed by catheter ablation 3 months post-surgery
Number of subjects: 260
Study 27776530 — intervention group
Group type: COMPARATOR
Intervention: Surgical CryoMaze alone
Number of subjects: 260
Study 24033306 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation practice for 5 days
Number of subjects: 0
Study 24033306 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 0
Study 24187870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sini injection (SG)
Number of subjects: 102
Study 24187870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DG)
Number of subjects: 102
Study 24187870 — intervention group
Group type: COMPARATOR
Intervention: Model group (MG)
Number of subjects: 102
Study 24187870 — intervention group
Group type: COMPARATOR
Intervention: Normal group (NG)
Number of subjects: 102
Study 24187870 — intervention group
Group type: COMPARATOR
Intervention: Sham operation group (OG)
Number of subjects: 102
Study 20842418 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 0
Study 20842418 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 0
Study 20842418 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-binding assay
Number of subjects: 0
Study 17952411 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg glycine
Number of subjects: 16
Study 17952411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16759769 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined DTaP-IPV vaccine
Number of subjects: 400
Study 16759769 — intervention group
Group type: COMPARATOR
Intervention: Separate DTaP and IPV vaccines
Number of subjects: 400
Study 14673985 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiography
Number of subjects: 43
Study 14673985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 43
Study 14673985 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 43
Study 14673985 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI
Number of subjects: 43
Study 14673985 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients with shoulder pain)
Number of subjects: 43
Study 10964860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 410
Study 10964860 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 410
Study 10964860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 8981527 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO administered subcutaneously three times weekly (group A)
Number of subjects: 33
Study 8981527 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO administered subcutaneously once weekly (group B)
Number of subjects: 33
Study 1282586 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 20
Study 1282586 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 20
Study 1282586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 4051273 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution A (tetracaine 0.5%, adrenalin 1:2,000, cocaine 11.8%)
Number of subjects: 0
Study 4051273 — intervention group
Group type: COMPARATOR
Intervention: Solution B (tetracaine 0.5%, adrenalin 1:2,000, no cocaine)
Number of subjects: 0
Study 4051273 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution A
Number of subjects: 0
Study 4051273 — intervention group
Group type: COMPARATOR
Intervention: Solution B
Number of subjects: 0
Study 31087556 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 120
Study 31087556 — intervention group
Group type: COMPARATOR
Intervention: Re-analysis of data from 95 cases
Number of subjects: 120
Study 29102571 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1815
Study 29102571 — intervention group
Group type: COMPARATOR
Intervention: Alternative therapy (prasugrel, ticagrelor)
Number of subjects: 1815
Study 27066777 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified verbal and written summaries of trial information
Number of subjects: 49
Study 27066777 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial information provided during antenatal period (suggested by women)
Number of subjects: 49
Study 24656562 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI with ovarian stimulation
Number of subjects: 65
Study 24656562 — intervention group
Group type: COMPARATOR
Intervention: IUI without ovarian stimulation followed by IUI with ovarian stimulation
Number of subjects: 65
Study 24656562 — intervention group
Group type: COMPARATOR
Intervention: IUI with natural/ovarian stimulation
Number of subjects: 65
Study 24656562 — intervention group
Group type: EXPERIMENTAL
Intervention: Preceding long-term pituitary down-regulation
Number of subjects: 65
Study 22295826 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanyinjiao (SP 6) acupuncture
Number of subjects: 16
Study 22295826 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 16
Study 20141300 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) plus treatment as usual (TAU)
Number of subjects: 27
Study 20141300 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 27
Study 18698140 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-based morphometry
Number of subjects: 50
Study 15842294 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportions of agreement
Number of subjects: 0
Study 15842294 — intervention group
Group type: EXPERIMENTAL
Intervention: Kappa for categorical variables
Number of subjects: 0
Study 15842294 — intervention group
Group type: EXPERIMENTAL
Intervention: Limits of agreement
Number of subjects: 0
Study 15842294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficient for continuous variables
Number of subjects: 0
Study 11865422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of quinolinic acid (QA)
Number of subjects: 261
Study 11865422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of picolinic acid (PA)
Number of subjects: 261
Study 11865422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of kynurenic acid (KA)
Number of subjects: 261
Study 11865422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) lactate levels
Number of subjects: 261
Study 11865422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of QA and PA
Number of subjects: 261
Study 10190653 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (10 mg-20 mg daily)
Number of subjects: 33
Study 10190653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 7759741 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (80% VO2max)
Number of subjects: 12
Study 7759741 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise (50% VO2max)
Number of subjects: 12
Study 2083097 — intervention group
Group type: EXPERIMENTAL
Intervention: Curosurf (200 mg/kg) via the tracheal tube
Number of subjects: 10
Study 2083097 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 infants)
Number of subjects: 10
Study 359248 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg diflunisal twice daily
Number of subjects: 57
Study 359248 — intervention group
Group type: EXPERIMENTAL
Intervention: 65 mg dextropropoxyphene plus 650 mg paracetamol 3-times daily
Number of subjects: 57
Study 359248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 31623851 — intervention group
Group type: EXPERIMENTAL
Intervention: Self condition - children waited to eat their food item to receive a second food item.
Number of subjects: 0
Study 31623851 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial condition - children waited to eat their food item to benefit another child.
Number of subjects: 0
Study 31623851 — intervention group
Group type: COMPARATOR
Intervention: Nonsocial Control condition - children waited to eat their food item with no benefit to anyone.
Number of subjects: 0
Study 31613825 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous estrogen exposure (EEE)
Number of subjects: 2114
Study 31613825 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) duration
Number of subjects: 2114
Study 31613825 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of HT initiation (within 5 years of menopause)
Number of subjects: 2114
Study 28658104 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution magnetic resonance cholangiopancreatography (HR‐MRCP) and T 2 ‐weighted imaging (HR‐T 2 WI)
Number of subjects: 41
Study 28658104 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter withdrawal
Number of subjects: 41
Study 26005742 — intervention group
Group type: EXPERIMENTAL
Intervention: Training video
Number of subjects: 75
Study 26005742 — intervention group
Group type: COMPARATOR
Intervention: Placebo video
Number of subjects: 75
Study 23043512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia combined with caudal block
Number of subjects: 260
Study 23043512 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia combined with caudal block
Number of subjects: 260
Study 23043512 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 260
Study 23043512 — intervention group
Group type: COMPARATOR
Intervention: Desflurane anesthesia
Number of subjects: 260
Study 22187760 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intramuscular ephedrine 0.5 mg/kg given 10 minutes before spinal anaesthesia
Number of subjects: 150
Study 22187760 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intramuscular ephedrine 0.5 mg/kg given 20 minutes before spinal anaesthesia
Number of subjects: 150
Study 22187760 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C) received only preloading with 15 ml/kg of Ringer lactate solution
Number of subjects: 150
Study 19101227 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in HDL cholesterol
Number of subjects: 3020
Study 19101227 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in triglycerides
Number of subjects: 3020
Study 19101227 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in LDL cholesterol
Number of subjects: 3020
Study 16304565 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Min Walk Test (6MWT)
Number of subjects: 22
Study 16304565 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Meter Walk Test (10MWT)
Number of subjects: 22
Study 16304565 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Index for Spinal Cord Injury II (WISCI II)
Number of subjects: 22
Study 16304565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Extremity Motor Score (LEMS)
Number of subjects: 22
Study 15277912 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 1380
Study 15277912 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 1380
Study 11488779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 60 mg/day
Number of subjects: 32
Study 11488779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 100 mg/day
Number of subjects: 32
Study 11488779 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 360 mg/day
Number of subjects: 32
Study 11488779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9669009 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% 38 ml + 10 mg midazolam (Group M10)
Number of subjects: 60
Study 9669009 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% 36 ml + 20 mg midazolam (Group M20)
Number of subjects: 60
Study 9669009 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.5% (Group C)
Number of subjects: 60
Study 8049691 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 5 mg + glycopyrrolate 300 micrograms
Number of subjects: 190
Study 8049691 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 5 mg + atropine 600 micrograms
Number of subjects: 190
Study 8049691 — intervention group
Group type: COMPARATOR
Intervention: diazepam 5 mg
Number of subjects: 190
Study 3291657 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone (167 patients)
Number of subjects: 326
Study 3291657 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation followed by 6 cycles of MOPP chemotherapy (159 patients)
Number of subjects: 326